Commentary: Implications of cancer managed as a "chronic illness"

Current Oncology Reports

Volumn 13, Issue 2, 2011, Pages 90-91

  Markman, Maurie ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Chemotherapy toxicity; Chronic disease; Cost of cancer care

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CHRONIC DISEASE; DISEASE SEVERITY; DRUG COST; DRUG INTERMITTENT THERAPY; DRUG SAFETY; GENE MUTATION; GENE OVEREXPRESSION; HEALTH INSURANCE; HEARING LOSS; HUMAN; LUNG NON SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; NEOPLASM; NOTE; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; SELF CARE; TREATMENT DURATION;

CHRONIC DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; UNITED STATES;

EID: 79955853238     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0148-6     Document Type: Note

References (3)

1. Markman M. Viewing ovarian cancer as a "chronic disease": What exactly does this mean? Gynecol Oncol 2006; 100:229-230.
2. Markman M. Limits to the "benefits" from our oncologic interventions. A case report. Gynecol Oncol 2000; 78:261-262.
3. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007; 25:180-186. (Pubitemid 350003031)